At what enterprise value was COOPER-VEMEDIA acquired in 2021?

During the acquisition of COOPER-VEMEDIA by CVC in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of COOPER-VEMEDIA when it was acquired by CVC?

The estimated EV/EBITDA multiple for COOPER-VEMEDIA is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was COOPER-VEMEDIA acquired by CVC?

COOPER-VEMEDIA was acquired by CVC in 2021.

What was the revenue of COOPER-VEMEDIA at the time of the deal?

The revenue of COOPER-VEMEDIA at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of COOPER-VEMEDIA during the acquisition?

COOPER-VEMEDIA's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the COOPER-VEMEDIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the COOPER-VEMEDIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/nos-exclus/la-vente-de-cooper-vemedia-devrait-se-deboucler-sur-un-nouveau-lbo-1279792

← DATABASE

Home Database Healthcare & PharmaCOOPER-VEMEDIA

03/2021

COOPER-VEMEDIA acquired by CVC

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs EV 1b - 4b EUR

Context

CVC acquired a majority stake in Cooper-Vemedia from Charterhouse. The transaction, valued at EUR2.2 billion, was won in a competitive process against a PAI/Ontario Teachers' consortium. The acquisition reflects CVC's appetite for high-cash-flow businesses with low capital intensity (Capex ~EUR10M). The goal is to pursue a buy-and-build strategy across Europe.

COOPER-VEMEDIA, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European consumer healthcare platform specialized in over-the-counter (OTC) treatments. Its portfolio includes iconic brands such as Oenobiol, Audispray, Mercurochrome, and Dakin. The group operates as both a manufacturer and a powerful distributor with a massive pharmacy network.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2021	NAXICAP PARTNERS	LAGARRIGUE	FRANCE	Implants & Prosthetics
04/2021	DIASORIN	LUMINEX CORPORATION	UNITED STATES	Diagnostic Equipment
02/2021	IK PARTNERS	Innovad Group	BELGIUM	Animal Health
02/2021	SIPAREX	WINNCARE	FRANCE	Medical Devices
01/2021	MONTAGU PRIVATE EQUITY	IMV TECHNOLOGIES	FRANCE	R&D Biotech
01/2021	SAGARD	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
01/2021	ARDIAN / BNP PARIBAS DEVELOPPEMENT	PROTEOR	FRANCE	Implants & Prosthetics
11/2020	NOVALPINA CAPITAL	LABORATOIRE X.O	FRANCE	Generics / Labs
10/2020	SULZER	HASELMEIER	SWITZERLAND	Medical Consumables
10/2020	ARDIAN	H2 PHARMA	FRANCE	CDMO

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of COOPER-VEMEDIA by CVC are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: cvc